Literature DB >> 29170080

Epilepsy in mucopolysaccharidosis disorders.

Maurizio Scarpa1, Charles Marques Lourenço2, Hernán Amartino3.   

Abstract

The mucopolysaccharidosis (MPS) disorders are caused by deficiencies of specific lysosomal enzymes involved in the catabolism of glycosaminoglycans (GAGs). The resulting GAG accumulation in cells and tissues throughout the body leads to progressive multi-organ dysfunction. MPS patients present with several somatic manifestations, including short stature, musculoskeletal abnormalities, and cardiorespiratory dysfunction, and several primary and secondary neurological signs and symptoms. Epileptic seizures are neurological signs of MPS thought to develop due to accumulation of GAGs in the brain, triggering alterations in neuronal connectivity and signaling, and release of inflammatory mediators. The amount of literature on the prevalence, pathophysiology, clinical features, and management of epileptic seizures in patients with MPS is limited. This review discusses current knowledge on this topic, as well as two case examples, presented and discussed during a closed meeting on MPS and the brain among an international group of experts with extensive experience in managing and treating MPS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Electroencephalography; Epilepsy; Lysosomal storage diseases; Mucopolysaccharidoses; Seizures

Mesh:

Substances:

Year:  2017        PMID: 29170080     DOI: 10.1016/j.ymgme.2017.10.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  9 in total

1.  Metabolic Disorders and Anesthesia.

Authors:  Cindy Yeoh; Howard Teng; Jacob Jackson; Lee Hingula; Takeshi Irie; Aron Legler; Corrine Levine; Iris Chu; Casey Chai; Luis Tollinche
Journal:  Curr Anesthesiol Rep       Date:  2019-07-12

Review 2.  Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.

Authors:  Yuji Sato; Torayuki Okuyama
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

Review 3.  Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.

Authors:  Haiyan Nan; Chanbum Park; Sungho Maeng
Journal:  Biomed Res Int       Date:  2020-12-04       Impact factor: 3.411

4.  Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS).

Authors:  Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2020-05-14       Impact factor: 4.123

Review 5.  Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses.

Authors:  Rita Barone; Alessandra Pellico; Annarita Pittalà; Serena Gasperini
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

6.  The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II).

Authors:  Miguel Sampayo-Cordero; Bernat Miguel-Huguet; Andrea Malfettone; José Manuel Pérez-García; Antonio Llombart-Cussac; Javier Cortés; Almudena Pardo; Jordi Pérez-López
Journal:  Int J Environ Res Public Health       Date:  2020-09-10       Impact factor: 3.390

7.  Glycosaminoglycans as Biomarkers for Mucopolysaccharidoses and Other Disorders.

Authors:  Paige C Amendum; Shaukat Khan; Seiji Yamaguchi; Hironori Kobayashi; Yasuhiko Ago; Yasuyuki Suzuki; Betul Celik; Estera Rintz; Jobayer Hossain; Wendi Xiao; Shunji Tomatsu
Journal:  Diagnostics (Basel)       Date:  2021-08-28

8.  Electroclinical Features of Epilepsy in Mucopolysaccharidosis III: Outcome Description in a Cohort of 15 Italian Patients.

Authors:  Rita Barone; Agata Fiumara; Mariangela Gulisano; Lara Cirnigliaro; Maria Donatella Cocuzza; Claudia Guida; Fabio Pettinato; Filippo Greco; Maurizio Elia; Renata Rizzo
Journal:  Front Neurol       Date:  2021-07-19       Impact factor: 4.003

Review 9.  Non-cardiac Manifestations in Adult Patients With Mucopolysaccharidosis.

Authors:  Karolina M Stepien; Andrew Bentley; Cliff Chen; M Wahab Dhemech; Edward Gee; Peter Orton; Catherine Pringle; Jonathan Rajan; Ankur Saxena; Govind Tol; Chaitanya Gadepalli
Journal:  Front Cardiovasc Med       Date:  2022-03-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.